Flotation

Yale University is in line to exit proteomics platform developer IsoPlexis in a Nasdaq Global Market offering with a $100m placeholder target.

The UChicago-backed digital home insurance provider is joining forces with Omnichannel Acquisition Corp at a valuation of just over $1bn.

Harvard spinout TScan Therapeutics has successfully listed on the Nasdaq Global Market.

The IGBMC spinout was set up by Satt Conectus and is now seeking a listing in the US with a price range of $15 to $17.

Th heart disease treatment developer has secured $248m in funding since being formed to exploit UT Southwestern and Gladstone Institute research.

University of Washington spinout Icosavax has filed for an initial public offering on the Nasdaq Global Select Market, with financial terms yet to be set.

Less than a year after raising $72.6m in its series A round, Aerovate Therapeutics has gone public following an IPO worth more than $121m.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.